Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications.

The company's mRNAi GOLD GalNAc Oligonucleotide Discovery platform that is used to target specific disease-associated genes in the liver.

Its siRNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell.

The company develops SLN360, which is in phase 2 clinical development to reduce high levels of lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and polycythemia vera.

It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform, as well as the company also collab with Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders.

The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007.

Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.